ConcertAI’s TeraRecon has introduced TeraRecon DETECT™, a new AI-driven platform designed to help healthcare organizations optimize reimbursement for multiple imaging biomarkers while improving clinical efficiency and patient outcomes. With many AI medical imaging innovations underutilized due to reimbursement challenges-only one-third of AI-related claims are reimbursed despite more than 1,000 FDA-cleared algorithms-hospitals have struggled to scale adoption. TeraRecon DETECT™ aims to close this critical gap by integrating seamlessly with existing Healthcare IT systems such as EMRs, imaging visualization tools, and reporting platforms to streamline prior authorization, automate eligibility validation, standardize diagnostics, and deliver real-time financial insights.
Also Read: SAIC and HavocAI Partner to Link Autonomous Fleets to U.S. Navy
“Launching TeraRecon DETECTTM isn’t just about equipping practitioners with the latest AI-empowered imaging capabilities but ensuring they have the clinical, operational and administrative support so that providing these services won’t be a burden to their organization or their patients,” said Eron Kelly, CEO of ConcertAI. The platform supports reimbursable AI biomarkers including FFR-CT, plaque analysis, MR prostate, bone density, and lung cancer screening. Dhiraj Carumbaya, SVP and General Manager of TeraRecon, emphasized the focus on elevating patient care, stating the solution helps clinicians “focus on what matters most – giving patients the most informed diagnoses and therefore driving up the standard of care.”